JP2024513522A5 - - Google Patents

Info

Publication number
JP2024513522A5
JP2024513522A5 JP2023562566A JP2023562566A JP2024513522A5 JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5 JP 2023562566 A JP2023562566 A JP 2023562566A JP 2023562566 A JP2023562566 A JP 2023562566A JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5
Authority
JP
Japan
Prior art keywords
cells
natural killer
population
combination
killer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562566A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513522A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023684 external-priority patent/WO2022216831A1/en
Publication of JP2024513522A publication Critical patent/JP2024513522A/ja
Publication of JP2024513522A5 publication Critical patent/JP2024513522A5/ja
Pending legal-status Critical Current

Links

JP2023562566A 2021-04-08 2022-04-06 Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療 Pending JP2024513522A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172414P 2021-04-08 2021-04-08
US63/172,414 2021-04-08
US202163290359P 2021-12-16 2021-12-16
US63/290,359 2021-12-16
PCT/US2022/023684 WO2022216831A1 (en) 2021-04-08 2022-04-06 Treatment of cancer with nk cells and a her2 targeted antibody

Publications (2)

Publication Number Publication Date
JP2024513522A JP2024513522A (ja) 2024-03-25
JP2024513522A5 true JP2024513522A5 (enExample) 2025-04-14

Family

ID=83545892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562566A Pending JP2024513522A (ja) 2021-04-08 2022-04-06 Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療

Country Status (6)

Country Link
US (1) US20240197778A1 (enExample)
EP (1) EP4319771A4 (enExample)
JP (1) JP2024513522A (enExample)
KR (1) KR20240024048A (enExample)
AU (1) AU2022254689A1 (enExample)
WO (1) WO2022216831A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102774451B1 (ko) 2017-11-14 2025-02-28 앱클론(주) 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체
AU2019381526B2 (en) 2018-11-14 2023-02-23 Green Cross Lab Cell Corporation Method for culturing cord blood-derived natural killer cells using transformed T-cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266726B2 (en) * 2015-10-30 2022-03-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for the treatment of HER2-expressing solid tumors
CN107267454B (zh) * 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
EP3463318A4 (en) * 2016-05-27 2020-01-01 TG Therapeutics Inc. COMBINATION OF ANTI-CD20-ANTIBODIES, P13-KINASE-DELTA-SELECTIVE INHIBITOR AND BTK-INHIBITOR FOR THE TREATMENT OF PROLIFERATIVE B-CELL DISORDERS
EP3567049A4 (en) * 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
AU2019271146A1 (en) * 2018-05-14 2020-12-10 Indapta Therapeutics, Inc. Subsets of human natural killer cells with enhanced antibody-directed immune responses

Similar Documents

Publication Publication Date Title
JP2024513958A5 (enExample)
JP2024513522A5 (enExample)
KR102883631B1 (ko) 감마-델타 t 세포 및 자연 살해 세포의 치료 제제 및 제조 및 사용 방법
Diorio et al. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks
JP2024515169A5 (enExample)
JP2024513514A5 (enExample)
Pistoia et al. Human γδ T-cells: from surface receptors to the therapy of high-risk leukemias
US6544787B1 (en) Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
JP2024527559A5 (enExample)
Tomuleasa et al. Chimeric antigen receptor T-cells for the treatment of B-cell acute lymphoblastic leukemia
US12060577B2 (en) Compositions for expanding natural killer cells
ES2224122T3 (es) Inmunoterapia de cancer con linfocitos alogenicos.
van Ostaijen-ten Dam et al. Preparation of cytokine-activated NK cells for use in adoptive cell therapy in cancer patients: protocol optimization and therapeutic potential
KR20140092298A (ko) 항 제3자 중심 기억 ｔ 세포, 이의 제조 방법, 및 이식 및 질환 치료에서의 이의 용도
Otegbeye et al. A phase I study to determine the maximum tolerated dose of ex vivo expanded natural killer cells derived from unrelated, HLA-disparate adult donors
CN115137752A (zh) 用于干细胞移植的方法
JP2022522231A5 (enExample)
PT2613801T (pt) Utilização de células t de memória central anti-terceiros no tratamento anti-leucemia/linfoma
Bader et al. Rapid immune recovery and low TRM in haploidentical stem cell transplantation in children and adolescence using CD3/CD19-depleted stem cells
EP1648508A1 (en) Methods and compositions for increasing the efficiency of therapeutic antibodies using alloreactive natural killer cells
JP2021516666A (ja) 前立腺がん特異的髄浸潤リンパ球およびその使用
AU2023257377A1 (en) Allogeneic t cells for treatment of hematological malignancies
JP2022023136A5 (enExample)
Gonzalez-Brito et al. The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies
US20210353674A1 (en) Pharmaceutical composition for use in the treatment of pancreatic cancer